Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. / Beier, Christoph Patrick; Rasmussen, Tine; Dahlrot, Rikke Hedegaard; Tenstad, Helene Broch; Aarø, Julie Slinning; Sørensen, Mai Froberg; Heimisdóttir, Sólborg Berglind; Sørensen, Mia Dahl; Svenningsen, Per; Riemenschneider, Markus J; Beier, Dagmar; Kristensen, Bjarne Winther.

I: Scientific Reports, Bind 8, Nr. 1, 08.10.2018, s. 14965.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Beier, CP, Rasmussen, T, Dahlrot, RH, Tenstad, HB, Aarø, JS, Sørensen, MF, Heimisdóttir, SB, Sørensen, MD, Svenningsen, P, Riemenschneider, MJ, Beier, D & Kristensen, BW 2018, 'Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival', Scientific Reports, bind 8, nr. 1, s. 14965. https://doi.org/10.1038/s41598-018-33282-5

APA

Beier, C. P., Rasmussen, T., Dahlrot, R. H., Tenstad, H. B., Aarø, J. S., Sørensen, M. F., Heimisdóttir, S. B., Sørensen, M. D., Svenningsen, P., Riemenschneider, M. J., Beier, D., & Kristensen, B. W. (2018). Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. Scientific Reports, 8(1), 14965. https://doi.org/10.1038/s41598-018-33282-5

Vancouver

Beier CP, Rasmussen T, Dahlrot RH, Tenstad HB, Aarø JS, Sørensen MF o.a. Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. Scientific Reports. 2018 okt. 8;8(1):14965. https://doi.org/10.1038/s41598-018-33282-5

Author

Beier, Christoph Patrick ; Rasmussen, Tine ; Dahlrot, Rikke Hedegaard ; Tenstad, Helene Broch ; Aarø, Julie Slinning ; Sørensen, Mai Froberg ; Heimisdóttir, Sólborg Berglind ; Sørensen, Mia Dahl ; Svenningsen, Per ; Riemenschneider, Markus J ; Beier, Dagmar ; Kristensen, Bjarne Winther. / Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. I: Scientific Reports. 2018 ; Bind 8, Nr. 1. s. 14965.

Bibtex

@article{1efe93efbedf4fda8f6ad902336f4f38,
title = "Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival",
abstract = "The mechanisms of glioma-associated seizures (GAS) have yet to be fully elucidated. Proneural subtype, isocitrate dehydrogenase 1 (IDH1) mutations, and epileptic seizures are closely associated suggesting that aberrant neuronal differentiation contributes to glioma-associated seizures. In a population-based cohort (n = 236), lack of stem cell marker expression (nestin, musashi) was significantly associated with IDH1 mutations and GAS at diagnosis. In vitro data suggested an association of IDH1 mutations and a more differentiated phenotype. Out of eight glioma stem cell (GSC) lines, seven revealed positivity for the synaptic marker protein synaptophysin. Three had synapse-like structures identified by electron microscopy and were either vGlut1 (glutamatergic) or GAD67 (GABAergic) positive. In vivo, >10% synaptophysin-positive tumour cells were present in >90% of all gliomas. Synaptophysin expression was associated with proneural subtype and vGlut1 expression, suggesting that most synapse-like structures in glioma are glutamatergic. However, we found null associations between vGlut1 protein/mRNA expression and survival, GAS at onset, development of GAS after resection, and refractory GAS. Synapse-like structures were neither functional nor activated by spontaneous action potentials or cellular networks. Thus, aberrant neuronal differentiation including glutamatergic synapse-like structures is detectable in glioma but is associated neither with epileptic seizures nor with better survival.",
author = "Beier, {Christoph Patrick} and Tine Rasmussen and Dahlrot, {Rikke Hedegaard} and Tenstad, {Helene Broch} and Aar{\o}, {Julie Slinning} and S{\o}rensen, {Mai Froberg} and Heimisd{\'o}ttir, {S{\'o}lborg Berglind} and S{\o}rensen, {Mia Dahl} and Per Svenningsen and Riemenschneider, {Markus J} and Dagmar Beier and Kristensen, {Bjarne Winther}",
year = "2018",
month = oct,
day = "8",
doi = "10.1038/s41598-018-33282-5",
language = "English",
volume = "8",
pages = "14965",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival

AU - Beier, Christoph Patrick

AU - Rasmussen, Tine

AU - Dahlrot, Rikke Hedegaard

AU - Tenstad, Helene Broch

AU - Aarø, Julie Slinning

AU - Sørensen, Mai Froberg

AU - Heimisdóttir, Sólborg Berglind

AU - Sørensen, Mia Dahl

AU - Svenningsen, Per

AU - Riemenschneider, Markus J

AU - Beier, Dagmar

AU - Kristensen, Bjarne Winther

PY - 2018/10/8

Y1 - 2018/10/8

N2 - The mechanisms of glioma-associated seizures (GAS) have yet to be fully elucidated. Proneural subtype, isocitrate dehydrogenase 1 (IDH1) mutations, and epileptic seizures are closely associated suggesting that aberrant neuronal differentiation contributes to glioma-associated seizures. In a population-based cohort (n = 236), lack of stem cell marker expression (nestin, musashi) was significantly associated with IDH1 mutations and GAS at diagnosis. In vitro data suggested an association of IDH1 mutations and a more differentiated phenotype. Out of eight glioma stem cell (GSC) lines, seven revealed positivity for the synaptic marker protein synaptophysin. Three had synapse-like structures identified by electron microscopy and were either vGlut1 (glutamatergic) or GAD67 (GABAergic) positive. In vivo, >10% synaptophysin-positive tumour cells were present in >90% of all gliomas. Synaptophysin expression was associated with proneural subtype and vGlut1 expression, suggesting that most synapse-like structures in glioma are glutamatergic. However, we found null associations between vGlut1 protein/mRNA expression and survival, GAS at onset, development of GAS after resection, and refractory GAS. Synapse-like structures were neither functional nor activated by spontaneous action potentials or cellular networks. Thus, aberrant neuronal differentiation including glutamatergic synapse-like structures is detectable in glioma but is associated neither with epileptic seizures nor with better survival.

AB - The mechanisms of glioma-associated seizures (GAS) have yet to be fully elucidated. Proneural subtype, isocitrate dehydrogenase 1 (IDH1) mutations, and epileptic seizures are closely associated suggesting that aberrant neuronal differentiation contributes to glioma-associated seizures. In a population-based cohort (n = 236), lack of stem cell marker expression (nestin, musashi) was significantly associated with IDH1 mutations and GAS at diagnosis. In vitro data suggested an association of IDH1 mutations and a more differentiated phenotype. Out of eight glioma stem cell (GSC) lines, seven revealed positivity for the synaptic marker protein synaptophysin. Three had synapse-like structures identified by electron microscopy and were either vGlut1 (glutamatergic) or GAD67 (GABAergic) positive. In vivo, >10% synaptophysin-positive tumour cells were present in >90% of all gliomas. Synaptophysin expression was associated with proneural subtype and vGlut1 expression, suggesting that most synapse-like structures in glioma are glutamatergic. However, we found null associations between vGlut1 protein/mRNA expression and survival, GAS at onset, development of GAS after resection, and refractory GAS. Synapse-like structures were neither functional nor activated by spontaneous action potentials or cellular networks. Thus, aberrant neuronal differentiation including glutamatergic synapse-like structures is detectable in glioma but is associated neither with epileptic seizures nor with better survival.

U2 - 10.1038/s41598-018-33282-5

DO - 10.1038/s41598-018-33282-5

M3 - Journal article

C2 - 30297697

VL - 8

SP - 14965

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -

ID: 364505101